<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01397890</url>
  </required_header>
  <id_info>
    <org_study_id>D589BL00023</org_study_id>
    <nct_id>NCT01397890</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>SECURE 1</acronym>
  <official_title>A Randomised, Parallel-group, Open-label, Multicentre, 3-month Phase IV, Efficacy and Tolerability Study of Budesonide/Formoterol (Symbicort® Turbuhaler® 160/4.5μg/Inhalation, 2 Inhalations Twice Daily) Added to Tiotropium (SpirivaTM 18 μg/Inhalation, 1 Inhalation Once Daily) Compared With Tiotropium (SpirivaTM18 μg/Inhalation, 1 Inhalation Once Daily) Alone in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This is a multicentre study with a randomised, parallel group, open-label, 3-month phase IV
      design to assess the efficacy and tolerability of Symbicort as an add-on treatment to Spiriva
      compare with Spiriva alone in patients with severe chronic obstructive pulmonary disease
      (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-dose FEV1</measure>
    <time_frame>Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug</time_frame>
    <description>Ratio of pre-dose FEV1 (Forced Expiratory Volume in 1 second) in treatment period to baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-dose FEV1 at 5 Minutes</measure>
    <time_frame>Baseline (-2 weeks) and mean in treatment period (1, 6, 12 weeks) measured at 5 minutes after inhalation of study drug</time_frame>
    <description>Ratio of post-dose FEV1 at 5 minutes to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose FEV1 at 60 Minutes</measure>
    <time_frame>Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
    <description>Ratio of post-dose FEV1 at 60 minutes to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose FVC</measure>
    <time_frame>Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
    <description>Ratio of pre-dose FVC (Forced Vital Capacity) in treatment period to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose FVC at 5 Minutes</measure>
    <time_frame>Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 5 minutes after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
    <description>Ratio of post-dose FVC at 5 minutes to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose FVC at 60 Minutes</measure>
    <time_frame>Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
    <description>Ratio of post-dose FVC at 60 minutes to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose IC</measure>
    <time_frame>Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug</time_frame>
    <description>Ratio of pre-dose IC (Inspiratory Capacity) in treatment period to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose IC at 60 Minutes</measure>
    <time_frame>Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
    <description>Ratio of post-dose IC at 60 minutes to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose PEF in Last Week of Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the last week of treatment, up to 12 weeks</time_frame>
    <description>Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to last week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose PEF in First Week of Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the first week of treatment</time_frame>
    <description>Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to first week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose PEF in Whole Treatment Period</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in whole treatment period of 12 weeks</time_frame>
    <description>Change in pre-dose morning PEF from run-in period to whole treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose PEF in Last Week of Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the last week of treatment, up to 12 weeks</time_frame>
    <description>Change in post-dose morning PEF at 5 minutes from run-period to last week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose PEF in First Week of Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the first week of treatment</time_frame>
    <description>Change in post-dose morning PEF at 5 minutes from run-in period to first week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose PEF in Whole Treatment Period</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in whole treatment period of 12 weeks</time_frame>
    <description>Change in post-dose morning PEF at 5 minutes from run-period to whole treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication During Day in the Last Week on Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment, up to 12 weeks</time_frame>
    <description>Change in the number of inhalations of reliever medication during day from run-in period to the last week on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication During Day in the First Week on Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the first week on treatment</time_frame>
    <description>Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication During Day in the Whole Treatment Period</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period of 12 weeks</time_frame>
    <description>Change in the number of inhalations of reliever medication during day from run-in period to the whole treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication During Night in the Last Week on Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment, up to 12 weeks</time_frame>
    <description>Change in the number of inhalations of reliever medication during night from run-in period to the last week on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication During Night in the First Week on Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the first week on treatment</time_frame>
    <description>Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication During Night in the Whole Treatment Period</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period of 12 weeks</time_frame>
    <description>Change in the number of inhalations of reliever medication during night from run-in period to the whole treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in COPD Symptoms - Breathing</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks</time_frame>
    <description>Change in breathing symptom score (from 0:none to 4:severe) from run-in period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in COPD Symptoms - Cough</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks</time_frame>
    <description>Change in Cough symptom score (from 0:none to 4:severe) from run-in period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in COPD Symptoms - Sputum</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks</time_frame>
    <description>Change in Sputum symptom score (from 0:none to 4:severe) from run-in period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Exacerbations</measure>
    <time_frame>Whole treatment period of 12 weeks</time_frame>
    <description>Severe exacerbations requiring systemic steroids (oral ≥3 days or parenteral) or hospitalisation or emergency room treatment due to worsening of COPD symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">793</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Add-on treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Add-on treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/formoterol (Symbicort® Turbuhaler®)</intervention_name>
    <description>Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium (SpirivaTM)</intervention_name>
    <description>Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Men or women patients ≥40 years of age

          -  Diagnosis of COPD with symptoms for more than 2 years and there is a history of at
             least one COPD exacerbation requiring a course of oral steroids and/or antibiotics
             within 1-12 months before Visit 2

          -  Forced Expiratory Volume in 1 second (FEV1) ≤50% of predicted normal value,
             pre-bronchodilator and Forced Expiratory Volume in 1 second (FEV1) / Forced Vital
             Capacity (FVC) &lt; 70%, pre-bronchodilator

          -  Total symptom score of 2 or more per day for at least half of run-in period
             (breathing, cough and sputum scores from the diary card) and complete morning
             recordings of Digital Peak Flow Meter data at least 7 out of the last 10 days of the
             run-in period

        Exclusion Criteria:

          -  A history of asthma and seasonal allergic rhinitis before 40 years of age

          -  Patients who have experienced exacerbation of COPD requiring hospitalisation and /or
             emergency room treatment and/or a course of oral steroids and/or intravenous
             corticosteroids and/or antibiotics within 4 weeks prior to Visit 2 and/or during
             run-in period and also the patients who use of systemic glucocorticosteroids (GCS)
             within 4 weeks and/or inhaled GCS within 2 weeks prior to Visit 2 and/or during run-in
             period

          -  Patients with relevant cardiovascular disorder judged by the investigator

          -  Patients with glaucoma, prostatic hyperplasia or bladder-neck obstruction judged by
             the investigator

          -  Women who are pregnant, breast-feeding or of child-bearing potential judged by the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Chen, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Pharmaceutical Co., Ltd., Shanghai, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shen Yang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guang Zhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kowloon</city>
        <state>HK</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Solo</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surabaya</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wonju-si</city>
        <state>Gangwon-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jinju-si</city>
        <state>Gyeongsangnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muang</city>
        <state>NAN</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chonburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nonthaburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phitsanulok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Songkhla</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Udon Thani</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Indonesia</country>
    <country>Korea, Republic of</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>July 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2011</study_first_posted>
  <results_first_submitted>June 18, 2014</results_first_submitted>
  <results_first_submitted_qc>August 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2014</results_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe chronic obstructive pulmonary disease (COPD) patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There are 793 patients enrolled. 578 patients were randomized, where there are 287 patients randomized in Symbicort+ Spiriva group and 291 in Spiriva group</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Symbicort+Spiriva</title>
          <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
        </group>
        <group group_id="P2">
          <title>Spiriva</title>
          <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="291"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Post-baseline Efficacy Data Collected</title>
              <participants_list>
                <participants group_id="P1" count="287">'Full Analysis Set' used for efficacy analysis</participants>
                <participants group_id="P2" count="290">'Full Analysis Set' used for efficacy analysis</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Correct Randomized Treatment</title>
              <participants_list>
                <participants group_id="P1" count="286">'Safety Analysis Set' =287+3-1=289. 3 and 1 pts in respective groups received opposite treatment.</participants>
                <participants group_id="P2" count="287">'Safety Analysis Set' =291+1-3=289.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="264"/>
                <participants group_id="P2" count="260"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility Criteria Not Fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition under Investigation Worsened</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe Non-Compliance to Protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Others</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Overall Number of Baseline Participants is not different from the Milestones.</population>
      <group_list>
        <group group_id="B1">
          <title>Symbicort+Spiriva</title>
          <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
        </group>
        <group group_id="B2">
          <title>Spiriva</title>
          <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="287"/>
            <count group_id="B2" value="290"/>
            <count group_id="B3" value="577"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.6" spread="7.99"/>
                    <measurement group_id="B2" value="66.9" spread="8.50"/>
                    <measurement group_id="B3" value="66.8" spread="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="279"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre-dose FEV1</title>
        <description>Ratio of pre-dose FEV1 (Forced Expiratory Volume in 1 second) in treatment period to baseline value</description>
        <time_frame>Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose FEV1</title>
          <description>Ratio of pre-dose FEV1 (Forced Expiratory Volume in 1 second) in treatment period to baseline value</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.050" lower_limit="1.030" upper_limit="1.070"/>
                    <measurement group_id="O2" value="1.006" lower_limit="0.987" upper_limit="1.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>multiplicative ANCOVA model with treatment and country as fixed factors and baseline value as a (log-transformed) covariate</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.044</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.019</ci_lower_limit>
            <ci_upper_limit>1.069</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose FEV1 at 5 Minutes</title>
        <description>Ratio of post-dose FEV1 at 5 minutes to baseline value</description>
        <time_frame>Baseline (-2 weeks) and mean in treatment period (1, 6, 12 weeks) measured at 5 minutes after inhalation of study drug</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose FEV1 at 5 Minutes</title>
          <description>Ratio of post-dose FEV1 at 5 minutes to baseline value</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.128" lower_limit="1.109" upper_limit="1.147"/>
                    <measurement group_id="O2" value="1.045" lower_limit="1.028" upper_limit="1.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.079</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.057</ci_lower_limit>
            <ci_upper_limit>1.102</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose FEV1 at 60 Minutes</title>
        <description>Ratio of post-dose FEV1 at 60 minutes to baseline value</description>
        <time_frame>Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose FEV1 at 60 Minutes</title>
          <description>Ratio of post-dose FEV1 at 60 minutes to baseline value</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.164" lower_limit="1.144" upper_limit="1.185"/>
                    <measurement group_id="O2" value="1.072" lower_limit="1.053" upper_limit="1.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.086</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.062</ci_lower_limit>
            <ci_upper_limit>1.111</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose FVC</title>
        <description>Ratio of pre-dose FVC (Forced Vital Capacity) in treatment period to baseline value</description>
        <time_frame>Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose FVC</title>
          <description>Ratio of pre-dose FVC (Forced Vital Capacity) in treatment period to baseline value</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.032" lower_limit="1.017" upper_limit="1.047"/>
                    <measurement group_id="O2" value="1.013" lower_limit="0.999" upper_limit="1.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0570</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.018</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.999</ci_lower_limit>
            <ci_upper_limit>1.037</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose FVC at 5 Minutes</title>
        <description>Ratio of post-dose FVC at 5 minutes to baseline value</description>
        <time_frame>Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 5 minutes after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose FVC at 5 Minutes</title>
          <description>Ratio of post-dose FVC at 5 minutes to baseline value</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.096" lower_limit="1.081" upper_limit="1.110"/>
                    <measurement group_id="O2" value="1.044" lower_limit="1.030" upper_limit="1.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.050</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.033</ci_lower_limit>
            <ci_upper_limit>1.067</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose FVC at 60 Minutes</title>
        <description>Ratio of post-dose FVC at 60 minutes to baseline value</description>
        <time_frame>Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose FVC at 60 Minutes</title>
          <description>Ratio of post-dose FVC at 60 minutes to baseline value</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.116" lower_limit="1.100" upper_limit="1.132"/>
                    <measurement group_id="O2" value="1.059" lower_limit="1.044" upper_limit="1.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.054</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.036</ci_lower_limit>
            <ci_upper_limit>1.073</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose IC</title>
        <description>Ratio of pre-dose IC (Inspiratory Capacity) in treatment period to baseline value</description>
        <time_frame>Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose IC</title>
          <description>Ratio of pre-dose IC (Inspiratory Capacity) in treatment period to baseline value</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.042" lower_limit="1.017" upper_limit="1.068"/>
                    <measurement group_id="O2" value="1.022" lower_limit="0.998" upper_limit="1.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1956</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.990</ci_lower_limit>
            <ci_upper_limit>1.050</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose IC at 60 Minutes</title>
        <description>Ratio of post-dose IC at 60 minutes to baseline value</description>
        <time_frame>Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose IC at 60 Minutes</title>
          <description>Ratio of post-dose IC at 60 minutes to baseline value</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.154" lower_limit="1.129" upper_limit="1.180"/>
                    <measurement group_id="O2" value="1.087" lower_limit="1.064" upper_limit="1.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.062</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.035</ci_lower_limit>
            <ci_upper_limit>1.091</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose PEF in Last Week of Treatment</title>
        <description>Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to last week of treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the last week of treatment, up to 12 weeks</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose PEF in Last Week of Treatment</title>
          <description>Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to last week of treatment</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.753" lower_limit="7.306" upper_limit="24.200"/>
                    <measurement group_id="O2" value="-4.550" lower_limit="-13.154" upper_limit="4.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>20.303</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.904</ci_lower_limit>
            <ci_upper_limit>30.702</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose PEF in First Week of Treatment</title>
        <description>Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to first week of treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the first week of treatment</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose PEF in First Week of Treatment</title>
          <description>Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to first week of treatment</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.405" lower_limit="8.464" upper_limit="18.345"/>
                    <measurement group_id="O2" value="-0.182" lower_limit="-4.994" upper_limit="4.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>13.587</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.407</ci_lower_limit>
            <ci_upper_limit>19.766</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose PEF in Whole Treatment Period</title>
        <description>Change in pre-dose morning PEF from run-in period to whole treatment period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in whole treatment period of 12 weeks</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose PEF in Whole Treatment Period</title>
          <description>Change in pre-dose morning PEF from run-in period to whole treatment period</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.271" lower_limit="6.382" upper_limit="18.160"/>
                    <measurement group_id="O2" value="-5.198" lower_limit="-10.925" upper_limit="0.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>17.469</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.147</ci_lower_limit>
            <ci_upper_limit>24.791</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose PEF in Last Week of Treatment</title>
        <description>Change in post-dose morning PEF at 5 minutes from run-period to last week of treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the last week of treatment, up to 12 weeks</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose PEF in Last Week of Treatment</title>
          <description>Change in post-dose morning PEF at 5 minutes from run-period to last week of treatment</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.379" lower_limit="13.199" upper_limit="33.560"/>
                    <measurement group_id="O2" value="-3.049" lower_limit="-13.556" upper_limit="7.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>26.428</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.463</ci_lower_limit>
            <ci_upper_limit>39.393</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose PEF in First Week of Treatment</title>
        <description>Change in post-dose morning PEF at 5 minutes from run-in period to first week of treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the first week of treatment</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose PEF in First Week of Treatment</title>
          <description>Change in post-dose morning PEF at 5 minutes from run-in period to first week of treatment</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.412" lower_limit="9.349" upper_limit="25.476"/>
                    <measurement group_id="O2" value="0.220" lower_limit="-7.486" upper_limit="7.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>17.192</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.491</ci_lower_limit>
            <ci_upper_limit>26.894</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose PEF in Whole Treatment Period</title>
        <description>Change in post-dose morning PEF at 5 minutes from run-period to whole treatment period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in whole treatment period of 12 weeks</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose PEF in Whole Treatment Period</title>
          <description>Change in post-dose morning PEF at 5 minutes from run-period to whole treatment period</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.880" lower_limit="9.307" upper_limit="22.454"/>
                    <measurement group_id="O2" value="-2.591" lower_limit="-9.063" upper_limit="3.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>18.472</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.347</ci_lower_limit>
            <ci_upper_limit>26.596</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication During Day in the Last Week on Treatment</title>
        <description>Change in the number of inhalations of reliever medication during day from run-in period to the last week on treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment, up to 12 weeks</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication During Day in the Last Week on Treatment</title>
          <description>Change in the number of inhalations of reliever medication during day from run-in period to the last week on treatment</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>times/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.750" lower_limit="-0.935" upper_limit="0.566"/>
                    <measurement group_id="O2" value="-0.082" lower_limit="-0.267" upper_limit="0.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.668</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.900</ci_lower_limit>
            <ci_upper_limit>-0.437</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication During Day in the First Week on Treatment</title>
        <description>Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the first week on treatment</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication During Day in the First Week on Treatment</title>
          <description>Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>times/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.457" lower_limit="-0.598" upper_limit="-0.316"/>
                    <measurement group_id="O2" value="-0.082" lower_limit="-0.222" upper_limit="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.375</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.552</ci_lower_limit>
            <ci_upper_limit>-0.198</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication During Day in the Whole Treatment Period</title>
        <description>Change in the number of inhalations of reliever medication during day from run-in period to the whole treatment period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period of 12 weeks</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication During Day in the Whole Treatment Period</title>
          <description>Change in the number of inhalations of reliever medication during day from run-in period to the whole treatment period</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>times/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.685" lower_limit="-0.836" upper_limit="-0.533"/>
                    <measurement group_id="O2" value="-0.134" lower_limit="-0.284" upper_limit="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.551</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.741</ci_lower_limit>
            <ci_upper_limit>-0.361</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication During Night in the Last Week on Treatment</title>
        <description>Change in the number of inhalations of reliever medication during night from run-in period to the last week on treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment, up to 12 weeks</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication During Night in the Last Week on Treatment</title>
          <description>Change in the number of inhalations of reliever medication during night from run-in period to the last week on treatment</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>times/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.174" lower_limit="-0.299" upper_limit="-0.049"/>
                    <measurement group_id="O2" value="0.062" lower_limit="-0.062" upper_limit="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.236</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.391</ci_lower_limit>
            <ci_upper_limit>-0.082</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication During Night in the First Week on Treatment</title>
        <description>Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the first week on treatment</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication During Night in the First Week on Treatment</title>
          <description>Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>times/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.113" lower_limit="-0.206" upper_limit="-0.019"/>
                    <measurement group_id="O2" value="0.011" lower_limit="-0.081" upper_limit="0.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0372</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.124</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.240</ci_lower_limit>
            <ci_upper_limit>-0.007</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication During Night in the Whole Treatment Period</title>
        <description>Change in the number of inhalations of reliever medication during night from run-in period to the whole treatment period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period of 12 weeks</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication During Night in the Whole Treatment Period</title>
          <description>Change in the number of inhalations of reliever medication during night from run-in period to the whole treatment period</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>times/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.241" lower_limit="-0.336" upper_limit="-0.147"/>
                    <measurement group_id="O2" value="-0.010" lower_limit="-0.104" upper_limit="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.231</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.350</ci_lower_limit>
            <ci_upper_limit>-0.113</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in COPD Symptoms - Breathing</title>
        <description>Change in breathing symptom score (from 0:none to 4:severe) from run-in period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in COPD Symptoms - Breathing</title>
          <description>Change in breathing symptom score (from 0:none to 4:severe) from run-in period</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.372" lower_limit="-0.454" upper_limit="-0.290"/>
                    <measurement group_id="O2" value="-0.110" lower_limit="-0.191" upper_limit="-0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.262</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.364</ci_lower_limit>
            <ci_upper_limit>-0.159</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in COPD Symptoms - Cough</title>
        <description>Change in Cough symptom score (from 0:none to 4:severe) from run-in period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in COPD Symptoms - Cough</title>
          <description>Change in Cough symptom score (from 0:none to 4:severe) from run-in period</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.311" lower_limit="-0.394" upper_limit="-0.229"/>
                    <measurement group_id="O2" value="-0.169" lower_limit="-0.250" upper_limit="-0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0067</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.143</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.246</ci_lower_limit>
            <ci_upper_limit>-0.040</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in COPD Symptoms - Sputum</title>
        <description>Change in Sputum symptom score (from 0:none to 4:severe) from run-in period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in COPD Symptoms - Sputum</title>
          <description>Change in Sputum symptom score (from 0:none to 4:severe) from run-in period</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.216" lower_limit="-0.295" upper_limit="-0.136"/>
                    <measurement group_id="O2" value="-0.094" lower_limit="-0.173" upper_limit="-0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0171</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.122</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.222</ci_lower_limit>
            <ci_upper_limit>-0.022</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Exacerbations</title>
        <description>Severe exacerbations requiring systemic steroids (oral ≥3 days or parenteral) or hospitalisation or emergency room treatment due to worsening of COPD symptoms</description>
        <time_frame>Whole treatment period of 12 weeks</time_frame>
        <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort+Spiriva</title>
            <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
          </group>
          <group group_id="O2">
            <title>Spiriva</title>
            <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Exacerbations</title>
          <description>Severe exacerbations requiring systemic steroids (oral ≥3 days or parenteral) or hospitalisation or emergency room treatment due to worsening of COPD symptoms</description>
          <population>FAS (287 + 290); less number of patients analyzed was caused by missing values.</population>
          <units>exacerbations/participant/12 weeks</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.182" lower_limit="0.138" upper_limit="0.239"/>
                    <measurement group_id="O2" value="0.307" lower_limit="0.248" upper_limit="0.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>Poisson regression</method>
            <method_desc>Poisson regression model with treatment as a factor and the duration time in study as an offset variable morning PEF as a covariate</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.593</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.419</ci_lower_limit>
            <ci_upper_limit>0.839</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0167</p_value>
            <method>Regression, Cox</method>
            <method_desc>Time to the first COPD exacerbation</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.614</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.412</ci_lower_limit>
            <ci_upper_limit>0.916</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0196</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks of treatment period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Symbicort+Spiriva</title>
          <description>Budesonide/formoterol (Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva 18 μg/inhalation, 1 inhalation once daily)</description>
        </group>
        <group group_id="E2">
          <title>Spiriva</title>
          <description>Spiriva 18 μg/inhalation, 1 inhalation once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Gingival oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperplastic cholecystopathy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Open wound</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Sputum abnormal</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI Disclosure Restriction is indicated in the Clinical Study Agreement, please refer to this document of each PI and country.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nongluk Yimsuan</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>66 2 7397400 ext 429</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

